<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The ability of the DNA methyltransferase inhibitors (DNMTi) to induce terminal differentiation in fibroblasts was first noted by Taylor and Jones in 1979; Silverman and Holland reported hematologic improvement in patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) in 1993 </plain></SENT>
<SENT sid="1" pm="."><plain>That <z:chebi fb="0" ids="2038">azacitidine</z:chebi> improves survival in patients with high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> features compared with a combined comparator group of supportive care, low-dose <z:chebi fb="0" ids="28680">cytarabine</z:chebi>, and intensive <z:chebi fb="0" ids="28680">cytarabine</z:chebi> plus <z:chebi fb="0" ids="48120">anthracycline</z:chebi>, while inducing trilineage normalization in approximately 15% of patients makes the development of more potent, more specific drugs that behave like <z:chebi fb="0" ids="2038">azacitidine</z:chebi> imperative </plain></SENT>
<SENT sid="2" pm="?"><plain>The question is, how do the azanucleosides behave </plain></SENT>
</text></document>